Revance Therapeutics Inc
RVNC.O- Latest Trade
- trading higher15.28USD
- Change
- 0.15
- % Change
0.99%Positive
- Day Range
- 14.93 - 15.63
- 52-Week Range
- 11.27 - 33.83
As of Jun 25 2022. Values delayed up to 15 minutes
- Previous Close
- 15.13
- Open
- 15.29
- Volume
- 1,381,797.00
- 3 Month Average Trading Volume
- 15.98
- Shares Out (Mil)
- 72.77
- Market Cap
- 1,100.98
- Forward P/E
- -4.29
- Dividend Yield
- -99,999.99
Key Statistics
1.8 mean rating - 10 analysts
- P/E Excl. Extra Items (TTM)
- -99,999.99
- Price To Sales (TTM)
- 12.27
- Price To Book (Quarterly)
- 42.51
- Price To Cash Flow (Per Share TTM)
- -99,999.99
- Total Debt/Total Equity (Quarterly)
- 1,760.85
- Long Term Debt/Equity (Quarterly)
- 1,686.95
- Return On Investment (TTM)
- -45.91
- Return On Equity (TTM)
- -41.66
2021 (millions USD)
About Revance Therapeutics Inc
Company Information
Revance Therapeutics, Inc. is a commercial stage biotechnology company. The Company is focused on advanced aesthetic and therapeutic offerings, including neuromodulator product, DaxibotulinumtoxinA for Injection. The DaxibotulinumtoxinA for Injection combines a proprietary stabilizing peptide excipient with a purified botulinum toxin that does not contain human or animal-based components. The Company is also evaluating additional aesthetic and therapeutic indications for DaxibotulinumtoxinA for Injection including the full upper face, which includes glabellar lines, forehead lines and crow’s feet, and adult upper limb spasticity. It offers products and services for United States aesthetics practices, including the resilient hyaluronic acid (RHA) Collection of dermal fillers and OPUL. The RHA Collection of dermal fillers is a dermal filler for the correction of dynamic facial wrinkles and folds. OPUL’s product offering includes the point-of-sale platform, software and hardware terminal.
Address
7555 GATEWAY BLVD., 7555 Gateway Blvd.NEWARK, CA
94560
United States
Industry
Biotechnology & Drugs
Executive Leadership
- Angus Charles Russell
- Independent Chairman of the Board
- Dustin S. Sjuts
- President
- Mark J. Foley
- Chief Executive Officer, Director
- Tobin C. Schilke
- Chief Financial Officer
- Dwight Moxie
- Senior Vice President, General Counsel, Corporate Secretary
- Jill Beraud
- Independent Director
- Julian S. Gangolli
- Independent Director
- Carey O Connor Kolaja
- Independent Director
- Chris Nolet
- Independent Director
- Philip J. Vickers
- Independent Director
- Olivia C. Ware
- Independent Director
Latest News
- MarketsDick's Sporting, Dish Network, Bumble
U.S. stocks rose in volatile trading on Tuesday, with investors evaluating fast-paced developments around the crisis in Ukraine as the United States banned Russian oil and other energy imports over the invasion.
- MarketsBlue Apron, Baker Hughes, Luminar, cruise cos
U.S. stock indexes rose on Thursday on strong earnings reports, while bargain hunting boosted mega-cap growth companies after the Nasdaq index plunged into correction territory in the previous session.
Markets Performance
Official Data PartnerCommodities
| Future | Last | % Change |
|---|---|---|
| Gold | 1,825.70 | -- |
| Copper | 693.65 | 0.33%Negative |
| Brent Crude Oil | 113.12 | -- |
| CBOT Soybeans | 1,609.00 | 0.99%Positive |
Stocks
| Index | Last | % Change |
|---|---|---|
| S&P 500 | 3,911.74 | 3.06%Positive |
| Euro STOXX 50 | 3,533.17 | 2.82%Positive |
| FTSE 100 | 7,208.81 | 2.68%Positive |
| Nikkei 225 | 26,491.97 | 1.23%Positive |
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes